Cortellaro M, Boschetti C, Beggi P, Polli E E
Scand J Haematol. 1981 Feb;26(2):106-14. doi: 10.1111/j.1600-0609.1981.tb01632.x.
In the Anturane Reinfarction Italian Study the trend of some specific and quantitative haemostatic parameters is being investigated in different series of patients balanced for sulfinpyrazone and placebo. In a series of young male patients who had had myocardial infarction 6 months previously, it has been shown that the placebo treatment subsample presented shortened platelet production time (PPT), increased levels of plasma beta-thromboglobulin (beta-TG) and platelet factor 4 (PF4), and increased factor VIII related antigen (VIII:RAg) compared with a matched control group. A close correlation between plasma concentration of VIII:RAg and PPT was evidenced in the same treatment subsample. The sulfinpyrazone treatment subsample presented normalized PPT accompanied by reduction of VIII:RAg but not of beta-TG or PF4 levels.
在意大利安替匹林再梗死研究中，正在对不同系列经磺吡酮和安慰剂平衡处理的患者，研究某些特定和定量止血参数的变化趋势。在一组6个月前发生过心肌梗死的年轻男性患者中，已表明与匹配的对照组相比，安慰剂治疗亚组的血小板生成时间（PPT）缩短，血浆β-血小板球蛋白（β-TG）和血小板因子4（PF4）水平升高，以及因子VIII相关抗原（VIII:RAg）升高。在同一治疗亚组中，证明VIII:RAg血浆浓度与PPT之间存在密切相关性。磺吡酮治疗亚组的PPT恢复正常，同时VIII:RAg降低，但β-TG或PF4水平未降低。
